EP Patent

EP2505204A3 — Method of treating prostate cancer with the GnRH antagonist degarelix

Assigned to Ferring BV · Expires 2013-01-09 · 13y expired

What this patent protects

The invention provides uses and dosing regimens of a gonadotrophin releasing hormone (GnRH) antagonist for the treatment of prostate cancer in a subject who is at risk for cardiovascular disease.

USPTO Abstract

The invention provides uses and dosing regimens of a gonadotrophin releasing hormone (GnRH) antagonist for the treatment of prostate cancer in a subject who is at risk for cardiovascular disease.

Drugs covered by this patent

Patent Metadata

Patent number
EP2505204A3
Jurisdiction
EP
Classification
—
Expires
2013-01-09
Drug substance claim
No
Drug product claim
No
Assignee
Ferring BV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.